| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/15/2007 | WO2007002220A3 Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| 03/15/2007 | WO2007001211A3 Dicarbonic acid derivatives, metastasis inhibitors and agents increasing chemotherapeutic activity of anti-tumor preparations, method for enhancing the cytostatic efficiency and metastasis process inhibiting method |
| 03/15/2007 | WO2006138714A3 Naphthyridine compounds |
| 03/15/2007 | WO2006138528A3 Tricyclic opioid modulators |
| 03/15/2007 | WO2006136461A3 Non-steroidal progesterone receptor modulators |
| 03/15/2007 | WO2006136391A3 Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor |
| 03/15/2007 | WO2006135862A3 Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity |
| 03/15/2007 | WO2006135638A3 Tanaproget compositions containing ethinyl estradiol |
| 03/15/2007 | WO2006134613A3 Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors |
| 03/15/2007 | WO2006133941A3 Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| 03/15/2007 | WO2006131884A3 Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors |
| 03/15/2007 | WO2006131401A3 Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent |
| 03/15/2007 | WO2006128692A3 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system |
| 03/15/2007 | WO2006127284A3 Method of purifying apo-2 ligand/trail using crystallisation in the cold |
| 03/15/2007 | WO2006122954A3 Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid |
| 03/15/2007 | WO2006122769A3 Substituted spiro compounds and their use for producing pain-relief drugs |
| 03/15/2007 | WO2006121919A8 Methods of treating obsessive compulsive disorder |
| 03/15/2007 | WO2006121560A3 Methods and compositions for treatment of cns disorders |
| 03/15/2007 | WO2006119295A3 Compositions and methods for the treatment of neurodegenerative diseases |
| 03/15/2007 | WO2006116755A3 Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| 03/15/2007 | WO2006115690A3 Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions |
| 03/15/2007 | WO2006113097A3 Methods of facilitating cell survival using neurotrophin mimetics |
| 03/15/2007 | WO2006106437A8 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
| 03/15/2007 | WO2006105403A3 Treatment of eye disorders with sirtuin modulators |
| 03/15/2007 | WO2006105196A3 Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health |
| 03/15/2007 | WO2006104760A3 OPHTHALMIC COMPOSITIONS COMPRISING dDC |
| 03/15/2007 | WO2006103562A3 Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| 03/15/2007 | WO2006099451A3 Novel human, feline, chicken and other animal interferons and uses thereof |
| 03/15/2007 | WO2006091801A3 Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
| 03/15/2007 | WO2006091666A3 Methods and compositions for treating conditions of the eye |
| 03/15/2007 | WO2006091180A3 Fucoidan multiparticulate drug carrier systems |
| 03/15/2007 | WO2006087644A3 Macrolides with anti-inflammatory activity |
| 03/15/2007 | WO2006084275A3 Contact drug delivery system |
| 03/15/2007 | WO2006084083A3 Devices for delivering agents to a vaginal tract |
| 03/15/2007 | WO2006083477A3 Compounds for inflammation and immune-related uses |
| 03/15/2007 | WO2006081088A3 Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an nsaid |
| 03/15/2007 | WO2006060127A3 COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE |
| 03/15/2007 | WO2006047288A3 Asymmetric synthesis of dihydrobenzofuran derivatives |
| 03/15/2007 | WO2006044556A3 Dual inhibitors of lipoxygenase for treating diabetes |
| 03/15/2007 | WO2006036926B1 Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| 03/15/2007 | WO2006035416A3 Minicapsule formulations |
| 03/15/2007 | WO2006025069A8 Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
| 03/15/2007 | WO2006024823A9 Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
| 03/15/2007 | WO2006023496A3 Vaginal cream compositions, kits thereof and methods of using thereof |
| 03/15/2007 | WO2006023440A3 Mitotic kinesin inhibitors |
| 03/15/2007 | WO2005117990A3 Compositions and methods for treatment of vascular grafts |
| 03/15/2007 | WO2005117588A3 Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
| 03/15/2007 | WO2005115370A3 Compounds and methods for treating non-inflammatory pain using pparalpha agonists |
| 03/15/2007 | WO2005110358A3 Film-shaped estriol-containing medicament for oral administration |
| 03/15/2007 | WO2005063745A8 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 03/15/2007 | WO2005044186A3 Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |
| 03/15/2007 | WO2004072100A3 Nell peptide expression systems and bone formation activity of nell peptide |
| 03/15/2007 | WO2004024073A3 Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin |
| 03/15/2007 | WO2003082006A3 Methods and compositions for preventing obesity and obesity related disorders |
| 03/15/2007 | US20070061921 Transgenic cells |
| 03/15/2007 | US20070061909 Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
| 03/15/2007 | US20070060755 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates |
| 03/15/2007 | US20070060754 Alkoxy substituted imidazoquinolines |
| 03/15/2007 | US20070060746 Processes for preparation of 9,11 epoxy steroids and intermediates useful therein |
| 03/15/2007 | US20070060656 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof |
| 03/15/2007 | US20070060655 Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient |
| 03/15/2007 | US20070060654 Association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it |
| 03/15/2007 | US20070060653 Physiologic vaginal lubrication to optimize sperm survival and function |
| 03/15/2007 | US20070060652 Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators |
| 03/15/2007 | US20070060651 Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia |
| 03/15/2007 | US20070060650 Solid skin care composition comprising multiple layers |
| 03/15/2007 | US20070060649 Lysine salt of 4-[2-Ethoxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-2-methyl-phenoxy}-acetic acid; X-ray diffraction patterns; proliferator-activator receptor agonists; antilipemic agents; hypotensive agents; antidiabetic agents; cardiovascular disorders; Syndrome X |
| 03/15/2007 | US20070060648 Lipids from methanotrophic bacteria for cholesterol reduction |
| 03/15/2007 | US20070060647 Gene expression regulating agent |
| 03/15/2007 | US20070060646 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction |
| 03/15/2007 | US20070060645 Purification of cinacalcet |
| 03/15/2007 | US20070060644 Therapeutic curcumin derivatives |
| 03/15/2007 | US20070060643 Autoinducer compounds |
| 03/15/2007 | US20070060642 Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
| 03/15/2007 | US20070060641 Therapeutic agent |
| 03/15/2007 | US20070060640 Intermediates for making alkyl aminoalkoxybenzoyl)-2-benzofuranylacetate including 4-(p-Hydroxyphenyl)-3,9-dioxafluoren-2-one and its enol; esterifying 2-benzofuranylacetic acid, acylation with p-anisoyl chloride, demethylating to form the hydroxy group, hydrolyzing and lactonizing |
| 03/15/2007 | US20070060639 Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| 03/15/2007 | US20070060638 Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
| 03/15/2007 | US20070060637 Synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan |
| 03/15/2007 | US20070060636 High enantiomeric purity dexanabinol for pharmaceutical compositions |
| 03/15/2007 | US20070060635 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 03/15/2007 | US20070060634 Compounds and compositions to control abnormal cell growth |
| 03/15/2007 | US20070060633 Indazole-based compounds having trifluoromethyl and hydroxy-alkyl substitution at position 5; e.g. 2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol; inflammatory, allergic, or proliferative diseases |
| 03/15/2007 | US20070060632 Lofexidine |
| 03/15/2007 | US20070060631 2-cyanomethyl-5-(3-substituted phenyl or 5-substituted thien-2-yl)-2H-tetrazoles; agricultural fungicides such as for rice blast |
| 03/15/2007 | US20070060630 Producing an alkoxy(tetrazol-1-yl)benzaldehyde compound by reacting the corresponding 1-(alkoxyphenyl)-1H-tetrazole compound with hexamethylenetetramine in a sulfonic acid' solvent, followed by hydrolysis; safe, efficient process; intermediate for analgesics or anti-inflammatory agents |
| 03/15/2007 | US20070060629 Large conductance calcium-activated k channel opener |
| 03/15/2007 | US20070060628 Use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl] thiazolidine-2,4-dione |
| 03/15/2007 | US20070060627 Organic compounds |
| 03/15/2007 | US20070060626 5-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-phenyl}-3H-[1,3,4]oxadiazol-2-one; agonists and antiagonists; demylination diseases; metabolic diseases; antidiabetic agents (type 2); syndrom X; asthma; osteoarthritis; lupus; antiinflammatory agents; cardiovascular disorders; cachexia |
| 03/15/2007 | US20070060625 Methods of modulating intestinal fluid balance |
| 03/15/2007 | US20070060624 Novel bioisosteres of actinonin |
| 03/15/2007 | US20070060623 Acid secretion inhibitor |
| 03/15/2007 | US20070060622 Compositions and methods using proton pump inhibitors |
| 03/15/2007 | US20070060621 Methods and compositions for the administration of prodrugs of proton pump inhibitors |
| 03/15/2007 | US20070060620 Use of RAR retinoid agonists to increase sperm count and sperm mobility in males |
| 03/15/2007 | US20070060619 Nicotinamide-based kinase inhibitors |
| 03/15/2007 | US20070060618 Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
| 03/15/2007 | US20070060617 2-Methoxy-5(5-trifluoromethyl-tetrazol-1-yl-benzyl)-2s-phenyl-piperdin-3s-yl)-amine for the treatment of social phobia |
| 03/15/2007 | US20070060616 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds |